1. Home
  2. RGEN vs FUTU Comparison

RGEN vs FUTU Comparison

Compare RGEN & FUTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
    SELLHOLDBUYas of 4 days ago
  • FUTU
    SELLHOLDBUYas of 4 days ago
  • Stock Information
  • Founded
  • RGEN 1981
  • FUTU 2011
  • Country
  • RGEN United States
  • FUTU Hong Kong
  • Employees
  • RGEN N/A
  • FUTU N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • FUTU Investment Bankers/Brokers/Service
  • Sector
  • RGEN Health Care
  • FUTU Finance
  • Exchange
  • RGEN Nasdaq
  • FUTU Nasdaq
  • Market Cap
  • RGEN 7.6B
  • FUTU 11.6B
  • IPO Year
  • RGEN N/A
  • FUTU 2019
  • Fundamental
  • Price
  • RGEN $160.51
  • FUTU $87.53
  • Analyst Decision
  • RGEN Buy
  • FUTU Buy
  • Analyst Count
  • RGEN 12
  • FUTU 4
  • Target Price
  • RGEN $187.44
  • FUTU $85.50
  • AVG Volume (30 Days)
  • RGEN 521.6K
  • FUTU 1.6M
  • Earning Date
  • RGEN 02-19-2025
  • FUTU 03-13-2025
  • Dividend Yield
  • RGEN N/A
  • FUTU N/A
  • EPS Growth
  • RGEN N/A
  • FUTU 2.20
  • EPS
  • RGEN N/A
  • FUTU 4.09
  • Revenue
  • RGEN $633,513,000.00
  • FUTU $1,307,165,497.00
  • Revenue This Year
  • RGEN $2.28
  • FUTU $36.79
  • Revenue Next Year
  • RGEN $9.88
  • FUTU $17.27
  • P/E Ratio
  • RGEN N/A
  • FUTU $21.41
  • Revenue Growth
  • RGEN N/A
  • FUTU 11.68
  • 52 Week Low
  • RGEN $113.50
  • FUTU $43.61
  • 52 Week High
  • RGEN $211.13
  • FUTU $130.50
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 62.61
  • FUTU 58.46
  • Support Level
  • RGEN $150.23
  • FUTU $78.58
  • Resistance Level
  • RGEN $160.64
  • FUTU $83.55
  • Average True Range (ATR)
  • RGEN 6.76
  • FUTU 2.89
  • MACD
  • RGEN 1.14
  • FUTU 0.73
  • Stochastic Oscillator
  • RGEN 80.27
  • FUTU 89.84

Stock Price Comparison Chart: RGEN vs FUTU

RGEN
FUTU
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025050100150200250300350RGEN VS FUTU

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About FUTU Futu Holdings Limited

Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use